Upload
others
View
15
Download
0
Embed Size (px)
Citation preview
Ekso Bionics
copy 2021 Ekso Bionics Holdings Inc All Rights Reserved
HC Wainwright Global Life Sciences ConferenceMarch 9-10 2021
copy 2021 Ekso Bionics Inc Page 2
Forward looking statements
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements Forward-looking statements may include without limitation statements regarding (i) the plans objectives and expectations of management for future operations including plans objectives and expectations relating to the design development and commercialization of human exoskeletons (ii) a projection of financial results financial condition capital expenditures capital structure or other financial items (iii) the Companys future financial performance and (iv) the joint venture in China including its implementation and successful operation (v) number or percentage of patients or workers that could potentially benefit from the Companyrsquos products and (vi) the assumptions underlying or relating to any statement described in points (i) (ii) (iii) (iv) or (v) above Such forward-looking statements are not meant to predict or guarantee actual results performance events or circumstances and may not be realized because they are based upon the Companys current projections plans objectives beliefs expectations estimates and assumptions and are subject to a number of risks and uncertainties and other influences many of which the Company has no control over Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include without limitation the Companys inability to obtain adequate financing to fund the Companys operations and necessary to develop or enhance our technology the significant length of time and resources associated with the development of the Companys products the Companys failure to achieve broad market acceptance of the Companys products the failure of our sales and marketing organization or partners to market our products effectively adverse results in future clinical studies of the Companys medical device products the failure to obtain or maintain patent protection for the Companys technology failure to obtain or maintain regulatory approval to market the Companys medical devices lack of product diversification existing or increased competition regulatory intervention resulting in the inability of the Company to execute its strategic plans and the Companys failure to implement the Companys business plans or strategies These and other factors are identified and described in more detail in the Companys public filings with the Securities and Exchange Commission (SECrdquo) You should carefully read our Cautionary Note Regarding Forward-Looking Statements and the factors described in the Risk Factors section of the Companyrsquos public filings with the SEC to better understand the risks and uncertainties inherent in our business The Company does not undertake to update these forward-looking statements
Our MissionTo amplify human motion by
enhancing strength endurance and mobility across medical and industrial applications with advanced robotics
copy 2021 Ekso Bionics Inc Page 4
Therapy Advantages
Elevating the standard of care for Neurorehabilitation
EksoNR vs Standard of Carebull Higher quality stepsbull Higher dosagebull Reduced risk and load on physical therapistbull Improved patient safetybull Improved outcomes
ldquoThe patient went from taking a few steps with 3 physical therapists to taking hundreds of steps with just one therapistrdquo
ndash Diane Senior Physical TherapistRehabilitation Institute of Michigan
CLICK TO WATCH VIDEO
copy 2021 Ekso Bionics Inc Page 5
Global Patient Population
18-78m Global2 288k1 USpeople currently live with Spinal
Cord Injury (SCI)
69m Global5 28m6 USpeople suffer a Traumatic Brain Injury
(TBI) each year
4 httpswwwcdcgovstrokefactshtm5 httpswwwncbinlmnihgovpubmed297015566 httpswwwcdcgovmmwrvolumes66ssss6609a1htm7 httpswwwhealthlinecomhealthmultiple-sclerosisfacts-statistics-infographic1
Spinal Cord InjuryTraumatic Brain Injury
15m Global3 800k4 USpeople suffer a Stroke each year
Stroke Multiple Sclerosis
23m Global7 10m7 US
people currently live with Multiple Sclerosis (MS)
bull Cerebral Palsybull Parkinsonsbull Orthopedic and post-surgical
recoverybull Many others
Covered under current IFU
1 httpswwwncbinlmnihgovpmcarticlesPMC41798332 httpswwwnsciscuabedupublic_pagesFactsFiguresArchivesFacts20and20Figures20-202018pdf3 httpwwwstrokecenterorgpatientsabout-strokestroke-statistics
Other Potential Indications
ABI indication includes most causes of brain injuries bull Strokebull Brain tumorsbull Surgical injuriesbull Hypoxia Anoxia
bull TBIbull Aneurysmsbull Degenerative and metabolic conditionsbull Infections and surgical injuries
copy 2021 Ekso Bionics Inc Page 6
US Market Structure and Opportunity
Inpatient Rehab (IRF)~1300 centers
~10 penetrationAvg LOS 15-20 days
Long Term Acute Care (LTACH) ~600 centers
Pilots in progressAvg LOS 20+ days
Skilled Nursing Facility (SNF) ~15000 centers
Pilots in progressAvg LOS Indefinite
OutpatientAcute Care
Future market opportunityOutpatient and home are potential future target markets
HomeCommunitybull Assisted Livingbull Nursing Homebull Hospicebull Home-based rehab
Patient Service Intensity
63000 centersEarly progress
Avg LOS 5-7 Days
Current focus on inpatient rehabilitation As technology advances opportunities in assistance will develop
Post-Acute Care(current focus)
Annual Global Market Opportunity ~$650-$900m
copy 2021 Ekso Bionics Inc Page 7
Observed OutcomesIncreased heart rate exertion and metabolic responses seen with walking in EksoNRIncreased motor activity with more normalized and symmetrical training pattern when using EksoNRImproved gait speed walking distance and standing balance outside of EksoNRImproved mobility independence outside of EksoNR
1870+Patients Studied
2200+ Target Enrollment
58Spinal Cord Injury
23Stroke
8 Multiple Sclerosis5 Traumatic Brain Injury2 Cerebral Palsy13 Multiple Diagnoses
Complete
74 36Ongoing
110 Research Trials amp Clinical Outcomes Globally
THE MOST STUDIED EXOSKELETON
copy 2021 Ekso Bionics Inc Page 8
EksoNR can increase revenue by I Increase RevenuePatient
Patients can undergo longer treatment at higher reimbursement
II Attract New Patient VolumeEksoNR attracts incremental patients
III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput
Customer Case Studies
II Attract New Patients2
bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue
III Increase Patient Throughput2
bull Average length of stay (LOS) decreased from 159 days to 141 days
bull ~13 improvement in effective patient throughput
Economic DriversI Increase Revenue Patient1
1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)
EksoNR is strategic differentiator for Stroke Centers
Economic value proposition of
copy 2021 Ekso Bionics Inc Page 9
Adoption DriversDemonstrated Customer Value
bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics
Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing
+400 centers
Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale
170+250+ 30Centers with devicesDevices shipped Sites with multiple devices
US Adoption of
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 2
Forward looking statements
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements Forward-looking statements may include without limitation statements regarding (i) the plans objectives and expectations of management for future operations including plans objectives and expectations relating to the design development and commercialization of human exoskeletons (ii) a projection of financial results financial condition capital expenditures capital structure or other financial items (iii) the Companys future financial performance and (iv) the joint venture in China including its implementation and successful operation (v) number or percentage of patients or workers that could potentially benefit from the Companyrsquos products and (vi) the assumptions underlying or relating to any statement described in points (i) (ii) (iii) (iv) or (v) above Such forward-looking statements are not meant to predict or guarantee actual results performance events or circumstances and may not be realized because they are based upon the Companys current projections plans objectives beliefs expectations estimates and assumptions and are subject to a number of risks and uncertainties and other influences many of which the Company has no control over Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include without limitation the Companys inability to obtain adequate financing to fund the Companys operations and necessary to develop or enhance our technology the significant length of time and resources associated with the development of the Companys products the Companys failure to achieve broad market acceptance of the Companys products the failure of our sales and marketing organization or partners to market our products effectively adverse results in future clinical studies of the Companys medical device products the failure to obtain or maintain patent protection for the Companys technology failure to obtain or maintain regulatory approval to market the Companys medical devices lack of product diversification existing or increased competition regulatory intervention resulting in the inability of the Company to execute its strategic plans and the Companys failure to implement the Companys business plans or strategies These and other factors are identified and described in more detail in the Companys public filings with the Securities and Exchange Commission (SECrdquo) You should carefully read our Cautionary Note Regarding Forward-Looking Statements and the factors described in the Risk Factors section of the Companyrsquos public filings with the SEC to better understand the risks and uncertainties inherent in our business The Company does not undertake to update these forward-looking statements
Our MissionTo amplify human motion by
enhancing strength endurance and mobility across medical and industrial applications with advanced robotics
copy 2021 Ekso Bionics Inc Page 4
Therapy Advantages
Elevating the standard of care for Neurorehabilitation
EksoNR vs Standard of Carebull Higher quality stepsbull Higher dosagebull Reduced risk and load on physical therapistbull Improved patient safetybull Improved outcomes
ldquoThe patient went from taking a few steps with 3 physical therapists to taking hundreds of steps with just one therapistrdquo
ndash Diane Senior Physical TherapistRehabilitation Institute of Michigan
CLICK TO WATCH VIDEO
copy 2021 Ekso Bionics Inc Page 5
Global Patient Population
18-78m Global2 288k1 USpeople currently live with Spinal
Cord Injury (SCI)
69m Global5 28m6 USpeople suffer a Traumatic Brain Injury
(TBI) each year
4 httpswwwcdcgovstrokefactshtm5 httpswwwncbinlmnihgovpubmed297015566 httpswwwcdcgovmmwrvolumes66ssss6609a1htm7 httpswwwhealthlinecomhealthmultiple-sclerosisfacts-statistics-infographic1
Spinal Cord InjuryTraumatic Brain Injury
15m Global3 800k4 USpeople suffer a Stroke each year
Stroke Multiple Sclerosis
23m Global7 10m7 US
people currently live with Multiple Sclerosis (MS)
bull Cerebral Palsybull Parkinsonsbull Orthopedic and post-surgical
recoverybull Many others
Covered under current IFU
1 httpswwwncbinlmnihgovpmcarticlesPMC41798332 httpswwwnsciscuabedupublic_pagesFactsFiguresArchivesFacts20and20Figures20-202018pdf3 httpwwwstrokecenterorgpatientsabout-strokestroke-statistics
Other Potential Indications
ABI indication includes most causes of brain injuries bull Strokebull Brain tumorsbull Surgical injuriesbull Hypoxia Anoxia
bull TBIbull Aneurysmsbull Degenerative and metabolic conditionsbull Infections and surgical injuries
copy 2021 Ekso Bionics Inc Page 6
US Market Structure and Opportunity
Inpatient Rehab (IRF)~1300 centers
~10 penetrationAvg LOS 15-20 days
Long Term Acute Care (LTACH) ~600 centers
Pilots in progressAvg LOS 20+ days
Skilled Nursing Facility (SNF) ~15000 centers
Pilots in progressAvg LOS Indefinite
OutpatientAcute Care
Future market opportunityOutpatient and home are potential future target markets
HomeCommunitybull Assisted Livingbull Nursing Homebull Hospicebull Home-based rehab
Patient Service Intensity
63000 centersEarly progress
Avg LOS 5-7 Days
Current focus on inpatient rehabilitation As technology advances opportunities in assistance will develop
Post-Acute Care(current focus)
Annual Global Market Opportunity ~$650-$900m
copy 2021 Ekso Bionics Inc Page 7
Observed OutcomesIncreased heart rate exertion and metabolic responses seen with walking in EksoNRIncreased motor activity with more normalized and symmetrical training pattern when using EksoNRImproved gait speed walking distance and standing balance outside of EksoNRImproved mobility independence outside of EksoNR
1870+Patients Studied
2200+ Target Enrollment
58Spinal Cord Injury
23Stroke
8 Multiple Sclerosis5 Traumatic Brain Injury2 Cerebral Palsy13 Multiple Diagnoses
Complete
74 36Ongoing
110 Research Trials amp Clinical Outcomes Globally
THE MOST STUDIED EXOSKELETON
copy 2021 Ekso Bionics Inc Page 8
EksoNR can increase revenue by I Increase RevenuePatient
Patients can undergo longer treatment at higher reimbursement
II Attract New Patient VolumeEksoNR attracts incremental patients
III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput
Customer Case Studies
II Attract New Patients2
bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue
III Increase Patient Throughput2
bull Average length of stay (LOS) decreased from 159 days to 141 days
bull ~13 improvement in effective patient throughput
Economic DriversI Increase Revenue Patient1
1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)
EksoNR is strategic differentiator for Stroke Centers
Economic value proposition of
copy 2021 Ekso Bionics Inc Page 9
Adoption DriversDemonstrated Customer Value
bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics
Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing
+400 centers
Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale
170+250+ 30Centers with devicesDevices shipped Sites with multiple devices
US Adoption of
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
Our MissionTo amplify human motion by
enhancing strength endurance and mobility across medical and industrial applications with advanced robotics
copy 2021 Ekso Bionics Inc Page 4
Therapy Advantages
Elevating the standard of care for Neurorehabilitation
EksoNR vs Standard of Carebull Higher quality stepsbull Higher dosagebull Reduced risk and load on physical therapistbull Improved patient safetybull Improved outcomes
ldquoThe patient went from taking a few steps with 3 physical therapists to taking hundreds of steps with just one therapistrdquo
ndash Diane Senior Physical TherapistRehabilitation Institute of Michigan
CLICK TO WATCH VIDEO
copy 2021 Ekso Bionics Inc Page 5
Global Patient Population
18-78m Global2 288k1 USpeople currently live with Spinal
Cord Injury (SCI)
69m Global5 28m6 USpeople suffer a Traumatic Brain Injury
(TBI) each year
4 httpswwwcdcgovstrokefactshtm5 httpswwwncbinlmnihgovpubmed297015566 httpswwwcdcgovmmwrvolumes66ssss6609a1htm7 httpswwwhealthlinecomhealthmultiple-sclerosisfacts-statistics-infographic1
Spinal Cord InjuryTraumatic Brain Injury
15m Global3 800k4 USpeople suffer a Stroke each year
Stroke Multiple Sclerosis
23m Global7 10m7 US
people currently live with Multiple Sclerosis (MS)
bull Cerebral Palsybull Parkinsonsbull Orthopedic and post-surgical
recoverybull Many others
Covered under current IFU
1 httpswwwncbinlmnihgovpmcarticlesPMC41798332 httpswwwnsciscuabedupublic_pagesFactsFiguresArchivesFacts20and20Figures20-202018pdf3 httpwwwstrokecenterorgpatientsabout-strokestroke-statistics
Other Potential Indications
ABI indication includes most causes of brain injuries bull Strokebull Brain tumorsbull Surgical injuriesbull Hypoxia Anoxia
bull TBIbull Aneurysmsbull Degenerative and metabolic conditionsbull Infections and surgical injuries
copy 2021 Ekso Bionics Inc Page 6
US Market Structure and Opportunity
Inpatient Rehab (IRF)~1300 centers
~10 penetrationAvg LOS 15-20 days
Long Term Acute Care (LTACH) ~600 centers
Pilots in progressAvg LOS 20+ days
Skilled Nursing Facility (SNF) ~15000 centers
Pilots in progressAvg LOS Indefinite
OutpatientAcute Care
Future market opportunityOutpatient and home are potential future target markets
HomeCommunitybull Assisted Livingbull Nursing Homebull Hospicebull Home-based rehab
Patient Service Intensity
63000 centersEarly progress
Avg LOS 5-7 Days
Current focus on inpatient rehabilitation As technology advances opportunities in assistance will develop
Post-Acute Care(current focus)
Annual Global Market Opportunity ~$650-$900m
copy 2021 Ekso Bionics Inc Page 7
Observed OutcomesIncreased heart rate exertion and metabolic responses seen with walking in EksoNRIncreased motor activity with more normalized and symmetrical training pattern when using EksoNRImproved gait speed walking distance and standing balance outside of EksoNRImproved mobility independence outside of EksoNR
1870+Patients Studied
2200+ Target Enrollment
58Spinal Cord Injury
23Stroke
8 Multiple Sclerosis5 Traumatic Brain Injury2 Cerebral Palsy13 Multiple Diagnoses
Complete
74 36Ongoing
110 Research Trials amp Clinical Outcomes Globally
THE MOST STUDIED EXOSKELETON
copy 2021 Ekso Bionics Inc Page 8
EksoNR can increase revenue by I Increase RevenuePatient
Patients can undergo longer treatment at higher reimbursement
II Attract New Patient VolumeEksoNR attracts incremental patients
III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput
Customer Case Studies
II Attract New Patients2
bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue
III Increase Patient Throughput2
bull Average length of stay (LOS) decreased from 159 days to 141 days
bull ~13 improvement in effective patient throughput
Economic DriversI Increase Revenue Patient1
1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)
EksoNR is strategic differentiator for Stroke Centers
Economic value proposition of
copy 2021 Ekso Bionics Inc Page 9
Adoption DriversDemonstrated Customer Value
bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics
Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing
+400 centers
Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale
170+250+ 30Centers with devicesDevices shipped Sites with multiple devices
US Adoption of
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 4
Therapy Advantages
Elevating the standard of care for Neurorehabilitation
EksoNR vs Standard of Carebull Higher quality stepsbull Higher dosagebull Reduced risk and load on physical therapistbull Improved patient safetybull Improved outcomes
ldquoThe patient went from taking a few steps with 3 physical therapists to taking hundreds of steps with just one therapistrdquo
ndash Diane Senior Physical TherapistRehabilitation Institute of Michigan
CLICK TO WATCH VIDEO
copy 2021 Ekso Bionics Inc Page 5
Global Patient Population
18-78m Global2 288k1 USpeople currently live with Spinal
Cord Injury (SCI)
69m Global5 28m6 USpeople suffer a Traumatic Brain Injury
(TBI) each year
4 httpswwwcdcgovstrokefactshtm5 httpswwwncbinlmnihgovpubmed297015566 httpswwwcdcgovmmwrvolumes66ssss6609a1htm7 httpswwwhealthlinecomhealthmultiple-sclerosisfacts-statistics-infographic1
Spinal Cord InjuryTraumatic Brain Injury
15m Global3 800k4 USpeople suffer a Stroke each year
Stroke Multiple Sclerosis
23m Global7 10m7 US
people currently live with Multiple Sclerosis (MS)
bull Cerebral Palsybull Parkinsonsbull Orthopedic and post-surgical
recoverybull Many others
Covered under current IFU
1 httpswwwncbinlmnihgovpmcarticlesPMC41798332 httpswwwnsciscuabedupublic_pagesFactsFiguresArchivesFacts20and20Figures20-202018pdf3 httpwwwstrokecenterorgpatientsabout-strokestroke-statistics
Other Potential Indications
ABI indication includes most causes of brain injuries bull Strokebull Brain tumorsbull Surgical injuriesbull Hypoxia Anoxia
bull TBIbull Aneurysmsbull Degenerative and metabolic conditionsbull Infections and surgical injuries
copy 2021 Ekso Bionics Inc Page 6
US Market Structure and Opportunity
Inpatient Rehab (IRF)~1300 centers
~10 penetrationAvg LOS 15-20 days
Long Term Acute Care (LTACH) ~600 centers
Pilots in progressAvg LOS 20+ days
Skilled Nursing Facility (SNF) ~15000 centers
Pilots in progressAvg LOS Indefinite
OutpatientAcute Care
Future market opportunityOutpatient and home are potential future target markets
HomeCommunitybull Assisted Livingbull Nursing Homebull Hospicebull Home-based rehab
Patient Service Intensity
63000 centersEarly progress
Avg LOS 5-7 Days
Current focus on inpatient rehabilitation As technology advances opportunities in assistance will develop
Post-Acute Care(current focus)
Annual Global Market Opportunity ~$650-$900m
copy 2021 Ekso Bionics Inc Page 7
Observed OutcomesIncreased heart rate exertion and metabolic responses seen with walking in EksoNRIncreased motor activity with more normalized and symmetrical training pattern when using EksoNRImproved gait speed walking distance and standing balance outside of EksoNRImproved mobility independence outside of EksoNR
1870+Patients Studied
2200+ Target Enrollment
58Spinal Cord Injury
23Stroke
8 Multiple Sclerosis5 Traumatic Brain Injury2 Cerebral Palsy13 Multiple Diagnoses
Complete
74 36Ongoing
110 Research Trials amp Clinical Outcomes Globally
THE MOST STUDIED EXOSKELETON
copy 2021 Ekso Bionics Inc Page 8
EksoNR can increase revenue by I Increase RevenuePatient
Patients can undergo longer treatment at higher reimbursement
II Attract New Patient VolumeEksoNR attracts incremental patients
III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput
Customer Case Studies
II Attract New Patients2
bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue
III Increase Patient Throughput2
bull Average length of stay (LOS) decreased from 159 days to 141 days
bull ~13 improvement in effective patient throughput
Economic DriversI Increase Revenue Patient1
1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)
EksoNR is strategic differentiator for Stroke Centers
Economic value proposition of
copy 2021 Ekso Bionics Inc Page 9
Adoption DriversDemonstrated Customer Value
bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics
Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing
+400 centers
Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale
170+250+ 30Centers with devicesDevices shipped Sites with multiple devices
US Adoption of
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 5
Global Patient Population
18-78m Global2 288k1 USpeople currently live with Spinal
Cord Injury (SCI)
69m Global5 28m6 USpeople suffer a Traumatic Brain Injury
(TBI) each year
4 httpswwwcdcgovstrokefactshtm5 httpswwwncbinlmnihgovpubmed297015566 httpswwwcdcgovmmwrvolumes66ssss6609a1htm7 httpswwwhealthlinecomhealthmultiple-sclerosisfacts-statistics-infographic1
Spinal Cord InjuryTraumatic Brain Injury
15m Global3 800k4 USpeople suffer a Stroke each year
Stroke Multiple Sclerosis
23m Global7 10m7 US
people currently live with Multiple Sclerosis (MS)
bull Cerebral Palsybull Parkinsonsbull Orthopedic and post-surgical
recoverybull Many others
Covered under current IFU
1 httpswwwncbinlmnihgovpmcarticlesPMC41798332 httpswwwnsciscuabedupublic_pagesFactsFiguresArchivesFacts20and20Figures20-202018pdf3 httpwwwstrokecenterorgpatientsabout-strokestroke-statistics
Other Potential Indications
ABI indication includes most causes of brain injuries bull Strokebull Brain tumorsbull Surgical injuriesbull Hypoxia Anoxia
bull TBIbull Aneurysmsbull Degenerative and metabolic conditionsbull Infections and surgical injuries
copy 2021 Ekso Bionics Inc Page 6
US Market Structure and Opportunity
Inpatient Rehab (IRF)~1300 centers
~10 penetrationAvg LOS 15-20 days
Long Term Acute Care (LTACH) ~600 centers
Pilots in progressAvg LOS 20+ days
Skilled Nursing Facility (SNF) ~15000 centers
Pilots in progressAvg LOS Indefinite
OutpatientAcute Care
Future market opportunityOutpatient and home are potential future target markets
HomeCommunitybull Assisted Livingbull Nursing Homebull Hospicebull Home-based rehab
Patient Service Intensity
63000 centersEarly progress
Avg LOS 5-7 Days
Current focus on inpatient rehabilitation As technology advances opportunities in assistance will develop
Post-Acute Care(current focus)
Annual Global Market Opportunity ~$650-$900m
copy 2021 Ekso Bionics Inc Page 7
Observed OutcomesIncreased heart rate exertion and metabolic responses seen with walking in EksoNRIncreased motor activity with more normalized and symmetrical training pattern when using EksoNRImproved gait speed walking distance and standing balance outside of EksoNRImproved mobility independence outside of EksoNR
1870+Patients Studied
2200+ Target Enrollment
58Spinal Cord Injury
23Stroke
8 Multiple Sclerosis5 Traumatic Brain Injury2 Cerebral Palsy13 Multiple Diagnoses
Complete
74 36Ongoing
110 Research Trials amp Clinical Outcomes Globally
THE MOST STUDIED EXOSKELETON
copy 2021 Ekso Bionics Inc Page 8
EksoNR can increase revenue by I Increase RevenuePatient
Patients can undergo longer treatment at higher reimbursement
II Attract New Patient VolumeEksoNR attracts incremental patients
III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput
Customer Case Studies
II Attract New Patients2
bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue
III Increase Patient Throughput2
bull Average length of stay (LOS) decreased from 159 days to 141 days
bull ~13 improvement in effective patient throughput
Economic DriversI Increase Revenue Patient1
1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)
EksoNR is strategic differentiator for Stroke Centers
Economic value proposition of
copy 2021 Ekso Bionics Inc Page 9
Adoption DriversDemonstrated Customer Value
bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics
Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing
+400 centers
Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale
170+250+ 30Centers with devicesDevices shipped Sites with multiple devices
US Adoption of
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 6
US Market Structure and Opportunity
Inpatient Rehab (IRF)~1300 centers
~10 penetrationAvg LOS 15-20 days
Long Term Acute Care (LTACH) ~600 centers
Pilots in progressAvg LOS 20+ days
Skilled Nursing Facility (SNF) ~15000 centers
Pilots in progressAvg LOS Indefinite
OutpatientAcute Care
Future market opportunityOutpatient and home are potential future target markets
HomeCommunitybull Assisted Livingbull Nursing Homebull Hospicebull Home-based rehab
Patient Service Intensity
63000 centersEarly progress
Avg LOS 5-7 Days
Current focus on inpatient rehabilitation As technology advances opportunities in assistance will develop
Post-Acute Care(current focus)
Annual Global Market Opportunity ~$650-$900m
copy 2021 Ekso Bionics Inc Page 7
Observed OutcomesIncreased heart rate exertion and metabolic responses seen with walking in EksoNRIncreased motor activity with more normalized and symmetrical training pattern when using EksoNRImproved gait speed walking distance and standing balance outside of EksoNRImproved mobility independence outside of EksoNR
1870+Patients Studied
2200+ Target Enrollment
58Spinal Cord Injury
23Stroke
8 Multiple Sclerosis5 Traumatic Brain Injury2 Cerebral Palsy13 Multiple Diagnoses
Complete
74 36Ongoing
110 Research Trials amp Clinical Outcomes Globally
THE MOST STUDIED EXOSKELETON
copy 2021 Ekso Bionics Inc Page 8
EksoNR can increase revenue by I Increase RevenuePatient
Patients can undergo longer treatment at higher reimbursement
II Attract New Patient VolumeEksoNR attracts incremental patients
III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput
Customer Case Studies
II Attract New Patients2
bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue
III Increase Patient Throughput2
bull Average length of stay (LOS) decreased from 159 days to 141 days
bull ~13 improvement in effective patient throughput
Economic DriversI Increase Revenue Patient1
1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)
EksoNR is strategic differentiator for Stroke Centers
Economic value proposition of
copy 2021 Ekso Bionics Inc Page 9
Adoption DriversDemonstrated Customer Value
bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics
Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing
+400 centers
Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale
170+250+ 30Centers with devicesDevices shipped Sites with multiple devices
US Adoption of
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 7
Observed OutcomesIncreased heart rate exertion and metabolic responses seen with walking in EksoNRIncreased motor activity with more normalized and symmetrical training pattern when using EksoNRImproved gait speed walking distance and standing balance outside of EksoNRImproved mobility independence outside of EksoNR
1870+Patients Studied
2200+ Target Enrollment
58Spinal Cord Injury
23Stroke
8 Multiple Sclerosis5 Traumatic Brain Injury2 Cerebral Palsy13 Multiple Diagnoses
Complete
74 36Ongoing
110 Research Trials amp Clinical Outcomes Globally
THE MOST STUDIED EXOSKELETON
copy 2021 Ekso Bionics Inc Page 8
EksoNR can increase revenue by I Increase RevenuePatient
Patients can undergo longer treatment at higher reimbursement
II Attract New Patient VolumeEksoNR attracts incremental patients
III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput
Customer Case Studies
II Attract New Patients2
bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue
III Increase Patient Throughput2
bull Average length of stay (LOS) decreased from 159 days to 141 days
bull ~13 improvement in effective patient throughput
Economic DriversI Increase Revenue Patient1
1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)
EksoNR is strategic differentiator for Stroke Centers
Economic value proposition of
copy 2021 Ekso Bionics Inc Page 9
Adoption DriversDemonstrated Customer Value
bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics
Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing
+400 centers
Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale
170+250+ 30Centers with devicesDevices shipped Sites with multiple devices
US Adoption of
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 8
EksoNR can increase revenue by I Increase RevenuePatient
Patients can undergo longer treatment at higher reimbursement
II Attract New Patient VolumeEksoNR attracts incremental patients
III Increase Patient ThroughputPatients can improve faster increasing a centerrsquos throughput
Customer Case Studies
II Attract New Patients2
bull 8 increase in of Stroke Patients (45 incremental patients)bull Each patient represents $18000 of revenuebull EksoNR attracted over $850000 of new revenue
III Increase Patient Throughput2
bull Average length of stay (LOS) decreased from 159 days to 141 days
bull ~13 improvement in effective patient throughput
Economic DriversI Increase Revenue Patient1
1 Ekso Bionics Customer Internal Study2 Ekso Bionics Customer Internal Study (OhioHealth)
EksoNR is strategic differentiator for Stroke Centers
Economic value proposition of
copy 2021 Ekso Bionics Inc Page 9
Adoption DriversDemonstrated Customer Value
bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics
Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing
+400 centers
Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale
170+250+ 30Centers with devicesDevices shipped Sites with multiple devices
US Adoption of
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 9
Adoption DriversDemonstrated Customer Value
bull Creates differentiation indicates stroke commitmentbull Attracts new patientsbull Delivers positive economics
Network Operator Standardizationbull Early success with Kindred IRFsbull Trials with multiple network operators representing
+400 centers
Flexible Acquisition Options (Rental Model)bull Introduced rentals in 2018 50+ units placed to datebull Positioned as bridge to capital acquisitionbull ~85 of rentals historically have converted to a sale
170+250+ 30Centers with devicesDevices shipped Sites with multiple devices
US Adoption of
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 10
Addition of Subscription Offering
bull COVID-19 has put tremendous pressure on hospitalsrsquo capital budgets making capital purchases by hospitals and rehab centers more challenging
bull Ekso offering a subscription model make adoption decisions easier for customersbull Customer Benefits of Subscription Offering
bull Remove capital barriersbull Align incentives and share risks between customer and Eksobull Access to technology upgrade paths
bull Benefits to Ekso Bionicsbull Accelerate market adoption bull Develop a stable and predictable base of recurring revenuebull Increase sales efficiency and productivitybull Create lifetime relationships with customer
bull Other Implications bull Investment required in early years (potential to finance)bull Revenue growth potentially slower but unit adoption of contracted revenue growing faster
versus bull Eksorsquos clinical support critical to maintain high subscription renewal rates
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 11
Ekso Bionicsrsquo Global Presence
300+ centers 450+ devices shipped 130+ million steps amp counting
Direct
Distributor
Global HeadquartersRichmond CA
EMEA HeadquartersHamburg GE
APAC HeadquartersSingapore
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 12
Industrial Exoskeleton Opportunity
Customer Problembull In US over 45m work-related injuries per
year accounting for 104m million lost production days (lsquo17)
bull The top category of injuries is over-exertion due to lifting lowering and repetitive motions
bull Upper extremity injuries are the number one injury type with Shoulders and Arms represent 11 of workplace injuries
EVO provides power without the painbull Upper-body exoskeleton designed to
increase productivity and reduce fatiguebull Goal of eliminating work-related injuries to
the neck shoulder and backbull Reduce productivity and quality problems
associated with repetitive fatigue-related issues
EVO Value Propositions
bull Healthier workforce
bull Increased productivitybull Improved quality and craftsmanship
bull Reduced fatiguebull Increased endurance
bull Improved worker morale
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 13
Industrial exoskeleton opportunity
Market Opportunitybull Solution to a large and growing industrial
workforce problembull Initial target segments are Construction and
Food Manufacturing representing over 6m employees
bull Additional segments include warehousing logistics military utilities and mining
bull Current view of market opportunity in targeted segment is gt $5B annually
bull Existing solutions have yet to achieve product-market fit or gain significant customer traction
Manufacturing Employment 129m
Food Manufacturing 17m
Transportation Equipment 17m
Furniture 387k
Appliances 406k
Industrial Workforce Size
Construction Workers 56m
Electricians 866k
Carpenters 656k
Drywall installers 120k
Plumbers pipefitters 438k
Source US Bureau of Labor amp Statistics
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 14
Financial highlights
2017-2019 Progressbull Revenue Growth 38 CAGR for revenue from FY 2017 to
FY 2019 (43 CAGR for eksoHealth)
bull Improving Gross Margins Steady Gross Margin improvement from 28 in FY 2017 to ~57 in FY 2020
bull Operations Efficiencies Revenue and margin growth and operating efficiencies resulted in consistent reduction in cash used for operations from $312m in FY 2017 to $88m in FY 2020
2020 and Impact of COVID-19bull Capital budgets constrainedbull Customer purchase decisions delayedbull Utilization impacted
Eksorsquos responsebull Continued cost reduction efforts across the organization has
lowered cash utilization to $88m in FY 2020bull Virtual selling and training programs with focus on customer
acquisition cost reductions and efficienciesbull Flexible sales offerings and financing options
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials
copy 2021 Ekso Bionics Inc Page 15
Financial highlights
2020 Resultsbull $89m in revenue for FY 2020bull Continued improvement
in Gross Margin of 57 FY 2020 and +60 in 2Hrsquo20
bull FY 2020 cash utilization down $70m from 2019 or 45 YOY
bull $115m in equity financings and $129m in cash at YE 2020
bull In Q1rsquo21 we received gross proceeds of ~$40m from a public offering that strengthens our cash position and gives us runway to execute on our growth strategy
Ekso management financials